---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-039770"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:53:03.938817+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q1 net loss $10.6M; DefenCath NDA resubmitted to FDA for 6-month review

## Summary
- Q1 net loss $10.6M ($0.24/share) vs $7.0M loss in Q1 2022; operating expenses $11.0M, up 57% YoY due to pre-launch activities.
- DefenCath NDA resubmitted to FDA; classified as Type 2 resubmission with 6-month review cycle, target action date November 2023.
- CMS proposed rule grants DefenCath NTAP up to $17,111 per hospital stay, contingent on FDA approval by July 1, 2024.
- US Patent Office issued notice of allowance for DefenCath composition, extending IP protection to 2042.
- Cash and short-term investments $55.6M; management believes sufficient to fund operations through first half of 2024.

## SEC filing metadata
- accession: 0001213900-23-039770
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/0001213900-23-039770-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/ea178530-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-039770
- JSON: https://secwatch.observer/filing/0001213900-23-039770.json
- Plain text: https://secwatch.observer/filing/0001213900-23-039770.txt

## Key facts
- Earnings Releases
  CorMedix Inc. reported first quarter ended March 31, 2023 results: net income net loss of $10.6 million, EPS $0.24 per share.
  - Period: first quarter ended March 31, 2023
  - Net income: net loss of $10.6 million
  - EPS: $0.24 per share
  - Result: reported results
  source text: For the first quarter of 2023, CorMedix recorded a net loss of $10.6 million, or $0.24 per share, compared with a net loss of $7.0 million, or $0.18 per share, in the first quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1410098/000121390023039770/0001213900-23-039770-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.